Project Grant R01AG087529
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$871K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Florida International University provides $479,375 in funding to investigate the effects of a small molecule activator of autophagy, TPI-132, on insulin signaling, senescence, and neuropathology in mouse models of Alzheimer's disease. The goal is to determine if modulating the autophagy-lysosome pathway through TPI-132 can increase neuroprotection, mitigate insulin resistance and senescence, and...
This federal Project Grant award, provided by the National Institute on Aging under CFDA program 93.866 - Aging Research, supports a research study focused on understanding the mechanisms responsible for autophagy defects in neurons affected by Alzheimer's disease (AD). The $749,030 award, with a performance period from December 15, 2024 to November 30, 2029, will be used by the principal investigator at The Trustees of Columbia University in the City of New York to evaluate the effects of...
This Project Grant award, issued by the National Institute on Aging under CFDA 93.866 - Aging Research, aims to elucidate the molecular mechanisms underlying the neurodegenerative reprogramming of microglia, the brain's resident immune cells, in Alzheimer's disease (AD). The $442,357 grant will fund research to determine how cellular stress signaling pathways, specifically the Integrated Stress Response (ISR), epigenetically reprogram microglia in a way that exacerbates their neurodegenerative...
This Project Grant award from the National Institute on Aging's (NIA) Aging Research program (CFDA 93.866) provides $660,402 to the University of Maryland, Baltimore (UMB) to study the role of autophagy, a cellular process that recycles damaged components, in regulating lipid metabolism and inflammation in microglia during brain aging and neurodegenerative diseases like Alzheimer's disease (AD). The research aims to determine how microglial lipid phagocytosis inhibits autophagy, leading to the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD). The $460,625 grant will fund research at the University of Massachusetts Medical School to dissect the separate P53/P21 and P16 senescence pathways and their functional consequences in AD using human induced pluripotent stem cell-based models. The 2-year project will produce...
This $745,765 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the Icahn School of Medicine at Mount Sinai (ISMMS) in New York aims to investigate the effects of Alzheimer's disease (AD) risk genes and aging on human microglia activity and lipid metabolism. The key focus is on understanding how genetic variants associated with increased AD risk or longevity may impact microglia's ability to clear cholesterol/lipid-rich cellular debris, a critical...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the role of the NOX2 enzyme in mediating the brain dysfunction associated with Alzheimer's disease (AD). The $842,175 award, effective December 15, 2024 through November 30, 2029, will allow the J. David Gladstone Institutes, a non-profit biomedical research organization, to explore the potential of a novel NOX2 antagonist (GSK2795039) in mitigating AD-related pathologies such...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $810,596 to New York University School of Medicine to develop a novel "off-the-shelf" chimeric antigen receptor (CAR) macrophage therapy for Alzheimer's disease. The key products and services to be delivered include: Optimizing a protocol to robustly transdifferentiate human induced pluripotent stem cells (hiPSCs) into self-sustaining macrophage/microglia (iMi) cells. Engineering the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $246,248 to The Trustees of the University of Pennsylvania to investigate how disrupted autophagy (a cellular process) contributes to inflammation and plaque formation in Alzheimer's disease (AD). The research aims to better understand the molecular consequences of disrupted...